News Search Year - Any - 2026 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2009 2008 Archive September 3, 2019 Deciphera Pharmaceuticals Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares in Public Offering of Common Stock Archive August 19, 2019 Deciphera Pharmaceuticals Announces Closing of Public Offering of Common Stock Archive August 14, 2019 Deciphera Pharmaceuticals Announces Pricing of Public Offering of Common Stock Archive August 13, 2019 Deciphera Pharmaceuticals Announces Proposed Public Offering of Common Stock Archive August 13, 2019 Deciphera Pharmaceuticals Reports Positive Updated Phase 1 Data for Ripretinib in Gastrointestinal Stromal Tumors Archive August 13, 2019 Deciphera Pharmaceuticals Announces Positive Top-line Results from INVICTUS Pivotal Phase 3 Clinical Study of Ripretinib in Patients with Advanced Gastrointestinal Stromal Tumors Archive August 2, 2019 Deciphera Pharmaceuticals, Inc. Announces Second Quarter 2019 Financial Results Archive July 8, 2019 Deciphera Pharmaceuticals, Inc. Announces Appointment of Susan L. Kelley, M.D., to its Board of Directors Archive June 11, 2019 Deciphera Pharmaceuticals, Inc. and Zai Lab Limited Announce an Exclusive License Agreement for Ripretinib in Greater China Archive June 10, 2019 Deciphera Pharmaceuticals, Inc. Expands Pipeline with Potential First-in-Class Autophagy Inhibitor to Treat Mutant RAS Cancers
Archive September 3, 2019 Deciphera Pharmaceuticals Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares in Public Offering of Common Stock
Archive August 19, 2019 Deciphera Pharmaceuticals Announces Closing of Public Offering of Common Stock
Archive August 14, 2019 Deciphera Pharmaceuticals Announces Pricing of Public Offering of Common Stock
Archive August 13, 2019 Deciphera Pharmaceuticals Reports Positive Updated Phase 1 Data for Ripretinib in Gastrointestinal Stromal Tumors
Archive August 13, 2019 Deciphera Pharmaceuticals Announces Positive Top-line Results from INVICTUS Pivotal Phase 3 Clinical Study of Ripretinib in Patients with Advanced Gastrointestinal Stromal Tumors
Archive August 2, 2019 Deciphera Pharmaceuticals, Inc. Announces Second Quarter 2019 Financial Results
Archive July 8, 2019 Deciphera Pharmaceuticals, Inc. Announces Appointment of Susan L. Kelley, M.D., to its Board of Directors
Archive June 11, 2019 Deciphera Pharmaceuticals, Inc. and Zai Lab Limited Announce an Exclusive License Agreement for Ripretinib in Greater China
Archive June 10, 2019 Deciphera Pharmaceuticals, Inc. Expands Pipeline with Potential First-in-Class Autophagy Inhibitor to Treat Mutant RAS Cancers
